Moberg Pharma AB (publ) (MOB.ST)
- Previous Close
34.14 - Open
34.22 - Bid 33.40 x --
- Ask 33.60 x --
- Day's Range
32.30 - 35.50 - 52 Week Range
4.13 - 40.90 - Volume
133,246 - Avg. Volume
602,099 - Market Cap (intraday)
974.398M - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-1.33 - Earnings Date May 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 4, 2019
- 1y Target Est
23.00
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. The company develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.
www.mobergpharma.se10
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: MOB.ST
Performance Overview: MOB.ST
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MOB.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MOB.ST
Valuation Measures
Market Cap
954.60M
Enterprise Value
899.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.56
Enterprise Value/Revenue
884.84
Enterprise Value/EBITDA
-39.00
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-2.91%
Return on Equity (ttm)
-3.69%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-21.09M
Diluted EPS (ttm)
-1.33
Balance Sheet and Cash Flow
Total Cash (mrq)
60.55M
Total Debt/Equity (mrq)
0.78%
Levered Free Cash Flow (ttm)
-149.44M
Research Analysis: MOB.ST
Company Insights: MOB.ST
MOB.ST does not have Company Insights